PA
SRPT icon

Perceptive Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Perceptive Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,900
Closed -$249K – 197
2016
Q4 		$249K Buy
+10,900
New +$438K 0.02% 137
2016
Q3 		– Sell
-7,619,300
Closed -$145M – 214
2016
Q2 		$145M Buy
+7,619,300
New +$141M 10.07% 1
2016
Q1 		– Sell
-100,000
Closed -$3.86M – 182
2015
Q4 		$3.86M Buy
+100,000
New +$3.24M 0.29% 61
2014
Q1 		– Sell
-650,000
Closed -$13.2M – 141
2013
Q4 		$13.2M Buy
+650,000
New +$19.3M 1.59% 19
2013
Q3 		– Hold
0
– -$14.9M – 118
2013
Q2 		– Hold
0
– – – 14

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors's SRPT Position: Q2 2024 in Review

Perceptive Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 525,683 shares — an estimated $68.1M sold.

Perceptive Advisors first reported a position in SRPT in Q2 2013 and held it in 24 quarters. The position peaked at $209M in Q3 2016. 484 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Perceptive Advisors reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Perceptive Advisors sold 525,683 Sarepta Therapeutics shares in Q2 2024, an estimated $68.1M.
  • Perceptive Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 24 quarters.
  • Perceptive Advisors's Sarepta Therapeutics position peaked at $209M in Q3 2016.
  • 484 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.